zidesamtinib   Click here for help

GtoPdb Ligand ID: 12392

Synonyms: Example 5 [US383715659] | NVL-520 | NVL520
Compound class: Synthetic organic
Comment: This is the chemical structure for the INN zidesamtinib (a tyrosine kinase inhibitor that is intended as an antineoplastic agent). Zidesamtinib's structure matches that for the brain penetrant ROS1 inhibitor NVL-520, that was designed to overcome ROS1G2032R-mediated resistance to lorlatinib, entrectinib and crizotinib [1]. Objective tumour responses have been observed in 3 patients with ROS1 fusion-positive lung cancers (including with brain metastases) that were resistant to other tyrosine kinase inhibitor therapies [1]. Turning Point Therapeutics' repotrectinib has also shown promise against ROS1G2032R, but NVL-520 is proposed as a more suitable rival in terms of CNS adverse events.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 91.17
Molecular weight 419.46
XLogP 2.19
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCN1C2=C(CC3=NN(C)N=C3C4=CC=C(C=C4[C@@H](C)OC5=CC2=CN=C5N)F)C=N1
Isomeric SMILES CCN1N=CC2=C1C3=CC(O[C@H](C)C4=CC(F)=CC=C4C5=NN(C)N=C5C2)=C(N)N=C3
InChI InChI=1S/C22H22FN7O/c1-4-30-21-13(11-26-30)7-18-20(28-29(3)27-18)16-6-5-15(23)9-17(16)12(2)31-19-8-14(21)10-25-22(19)24/h5-6,8-12H,4,7H2,1-3H3,(H2,24,25)/t12-/m1/s1
InChI Key DTWUUAFTYSMNQX-GFCCVEGCSA-N
References
1. Drilon A, Horan JC, Tangpeerachaikul A, Besse B, Ou SI, Gadgeel SM, Camidge DR, van der Wekken AJ, Nguyen-Phuong L, Acker A et al.. (2023)
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
Cancer Discov, 13 (3): 598-615. [PMID:36511802]
2. Horan JC, Tang X, Mente SR, Pelish HE, Shair MD, Tangpeerachaikul A. (2023)
Heteroaromatic macrocyclic ether chemotherapeutic agents.
Patent number: US11542278. Assignee: Nuvalent, Inc.. Priority date: 29/10/2021. Publication date: 03/01/2023.